Industry
Biotechnology
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Loading...
Open
15.64
Mkt cap
1.6B
Volume
570K
High
16.24
P/E Ratio
-34.34
52-wk high
17.08
Low
15.28
Div yield
N/A
52-wk low
3.38
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 1:30 pm
Portfolio Pulse from Vandana Singh
August 23, 2024 | 3:43 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 3:40 pm
Portfolio Pulse from Vandana Singh
August 20, 2024 | 4:21 pm
Portfolio Pulse from Avi Kapoor
August 20, 2024 | 2:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 9:43 am
Portfolio Pulse from Benzinga Insights
August 19, 2024 | 5:30 pm
Portfolio Pulse from Avi Kapoor
August 13, 2024 | 3:44 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:25 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.